Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 92   

Articles published

ALKS 58.27 +2.06 (3.66%)
price chart
Roanoke Asset Management Corp NY Sells 22920 Shares of Alkermes PLC (ALKS)
Alkermes PLC logo Roanoke Asset Management Corp NY decreased its position in shares of Alkermes PLC (NASDAQ:ALKS) by 21.8% during the third quarter, according to its most recent 13F filing with the SEC.
Why Alkermes PLC Skyrocketed Today
Alkermes tested ALKS 5461 in patients with major depressive disorder who haven't been helped by other drugs. At the higher dose, ALKS 5461 improved symptoms of depression -- based on two different scales used by doctors -- compared with placebo.
Alkermes plc (ALKS) Announces Third ALKS 5461 Phase 3 Met Primary Endpoint ...
Credit Suisse Bullish on Alkermes Plc (ALKS) as It Takes a Leap FORWARD  Smarter Analyst
Alkermes PLC (ALKS) CAO Kathryn L. Biberstein Sells 15000 Shares
Alkermes PLC logo Alkermes PLC (NASDAQ:ALKS) CAO Kathryn L. Biberstein sold 15,000 shares of the firm's stock in a transaction that occurred on Thursday, December 1st.
Insider Selling: Alkermes PLC (ALKS) SVP Sells $575100.00 in Stock  Sports Perspectives
Kathryn L. Biberstein Sells 15000 Shares of Alkermes PLC (ALKS) Stock
Alkermes PLC logo Alkermes PLC (NASDAQ:ALKS) CAO Kathryn L. Biberstein sold 15,000 shares of the company's stock in a transaction dated Thursday, December 1st.
Michael J. Landine Sells 10000 Shares of Alkermes PLC (ALKS) Stock
Alkermes PLC logo Alkermes PLC (NASDAQ:ALKS) SVP Michael J. Landine sold 10,000 shares of Alkermes PLC stock in a transaction that occurred on Wednesday, November 30th.
Richard F. Pops Sells 30000 Shares of Alkermes PLC (ALKS) Stock  BBNS
Insider Filing Note: Warning Alkermes Plc (NASDAQ:ALKS) optimists! Kathryn ...  Thorold News
Notable Runners: Alkermes plc (NASDAQ:ALKS), Level 3 Communications, Inc ...
Alkermes plc (NASDAQ:ALKS) ended its previous trading session at $56.21 with the Loss of -0.07%. The company's market cap is $8.52 Billion, and the average volume is $1.2 Million.
Alkermes PLC: Sales Rise, Losses Fall, and the Pipeline Moves Forward
Alkermes (NASDAQ:ALKS), a biopharmaceutical company that specializes in extended-release drug delivery technology, reported third-quarter results on Nov. 2 and provided investors with an update on its pipeline.
Alkermes plc Risk Points versus Health Care
This is a scatter plot analysis of the critical risk points from the option market for Alkermes plc (NASDAQ:ALKS) compared to its own past and the Health Care ETF.
Insider Heat: Is Alkermes Plc (NASDAQ:ALKS) Stock a Sell after Michael Landine ...
As disclosed in a public form that's filled with the U.S. SEC on 30-11-2016, Michael Landine an insider in Alkermes Plc. and currently SVP - Corp Dev. - Alkermes - Inc., sold shares worth $575,083 U.S. Dollars in the Ireland-based Alkermes Plc. He sold ...
Alkermes PLC (ALKS) Position Increased by Wells Fargo & Company MN  The Cerbat Gem
The Zacks Investment Research lowers the Stock rating of Alkermes PLC (ALKS)  DailyQuint
Alkermes PLC (ALKS) Receives Average Recommendation of "Buy" from Analysts
Alkermes PLC logo Shares of Alkermes PLC (NASDAQ:ALKS) have been given an average recommendation of “Buy” by the twelve analysts that are covering the company.